Rethinking the role of bisphosphonates after denosumab treatment in locally advanced or unresectable aneurysmal bone cysts: A meta-analysis

Table 2 Demographics, tumor characteristics, treatment details and outcomes in two groups, n (%)/median (range)

Feature	Group 1 (n = 31)	Group 2 (n = 12)	P value
Gende			0.3
Male	18 (58)	9 (75)
Female	13 (42)	3 (25)
Age (years)	16 (5-42)	10.5 (8-16)	0.03
Site			0.2
Axial	23 (74)	11 (92)
Extremities	8 (26)	1 (8)
Primary/failed initial treatment/poor response	22 (71)	7 (58)	0.4
Recurrent	9 (29)	5 (42)
DT duration (months)	12 (4-41)	15 (10-27)	0.05
Clinical and/or imaging response to DT			0.9
Yes	27 (90)	10 (91)
No	3 (10)	1 (9)
Post-DT withdrawal follow-up (months)	16 (3-43)	12 (6-42)	0.4
Clinical and/or imaging and/or histological relapse			0.02
Yes	10 (32)	0 (0)
No	21 (68)	12 (100)

DT: Denosumab treatment.